2nd Quarter - Report

KNIGHT CAPITOL CONSULTANTS for PHRMA

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

Patent Reform -- issues of interest to the pharmaceutical industry (S. 515/H.R. 1260) Provisions in legislation affecting agreements between pharmaceutical companies to settle patent infringement lawsuits (S. 369/H.R. 3962/H.R. 3590/H.R. 4899)

LobbyistCovered position, as disclosed
PATRICIA KNIGHT Prof. Staff, House Appropr. Committee

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 3590 (111th), H.R. 3962 (111th), H.R. 1260 (111th), S. 369 (111th), H.R. 4899 (111th), S. 515 (111th)

Taxation/Internal Revenue Code TAX

Research and Development tax credit extension, and possible changes to pharmaceutical reimbursement provisions (H.R. 5297, small business lending; H.R.4213, tax extenders)

LobbyistCovered position, as disclosed
PATRICIA KNIGHT previously listed

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5297 (111th), H.R. 4213 (111th)

Health Issues HCR

Health Care Reform - efforts to amend or implement pharmaceutical provisions of the Patient Protection and Affordable Health Care Act (PL 111-148) and the Health Care and Education Reconciliation Act of 2010 (PL 111-152), including comparative effectiveness, prescription drug importation, reimbursement.

LobbyistCovered position, as disclosed
PATRICIA KNIGHT previously listed

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.